Luciana Griebel

Luciana brings an in-house perspective from time spent in the legal department of a global pharmaceutical company and with a mobile-first games powerhouse. Fluent in many languages, Luciana speaks English, French, German, Italian, Romanian, and Spanish.

Beyond her private practice, Luciana does pro bono work for charities in which she advises on a range of corporate matters, including one focused on the development of renewable energy technologies in Africa and South America as well as a leading UK children’s charity.

She is an active member of the American Bar Association (ABA), currently serving as vice-chair of its International M&A Subcommittee and editor of Deal Points, the publication of the ABA’s M&A Committee.

• Represented a major pharmaceutical company in its €2.1 billion ($2.3 billion) acquisition of a maker of digital identification products for animals
• Represented a major pharmaceutical company in its acquisition of a SARS-CoV-2 vaccine candidate developer
• Represented a major pharmaceutical company in its $425 million acquisition of a clinical-stage biopharmaceutical company
• Represented a major pharmaceutical company in its global separation in preparation for a $9 billion spin-off of its therapeutic products business
• Represented a major pharmaceutical company in its multiyear global merger integration with a drug maker
• Represented a major pharmaceutical company in its strategic oncology collaboration with a biotech company, including with respect to its acquisition of a 9% interest in the company
• Represented a developer of drug-aerosol therapeutics, along with existing shareholders and founders, on its sale to a pharmaceutical company for up to a total of €500 million ($551.5 million) subject to regulatory and sales milestones with an upfront payment of €140 million ($154.4 million)
• Represented a clinical-stage biopharmaceutical company on its sale to a pharmaceutical company
• Represented a major pharmaceutical company in its divestment of global rights to a consumer brand to a consumer healthcare company
• Represented a major pharmaceutical company in the sale of its portfolio of over-the-counter products in certain European countries to a European pharmaceutical company
• Represented a major pharmaceutical company in its acquisition of an asset-centric biopharmaceutical company
• Represented a global power management company in its $2.83 billion acquisition of an air-to-air refueling system manufacturer
• Represented a semiconductor manufacturer on its €4.9 billion ($5.4 billion) acquisition of a semiconductor company
• Represented a technology company on its £1.56 billion ($2.04 billion) recommended cash offer for a semiconductor company
• Represented a media and entertainment company in the $262.2 million sale of its broadcast operations in Croatia and Slovenia
• Represented a fashion brand in its collaboration with a listed Dubai property company for the development of a worldwide chain of hotels and resorts
• Represented the management team of a software company on its investment from a private equity firm under the terms of which the firm assumed majority ownership from another private equity company for an enterprise value of £200 million ($312 million)